BALA CYNWYD, Pa., May 19, 2017 (GLOBE NEWSWIRE) — Hamilton Lane (NASDAQ:HLNE) announced today that J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, the joint book-running managers in Hamilton Lane’s recent initial public offering of Class A common stock, have agreed to waive a lock-up restriction to permit an officer of Hamilton Lane to exercise his options to purchase 233,495 shares of Hamilton Lane’s Class A common stock (the “Options”). Any shares of Class A common stock received by such officer pursuant to the exercise of the Options will remain subject to lock-up restrictions for the term of the lock-up agreement. The waiver will take effect on May 23, 2017. The existence of the Options was previously disclosed in Hamilton Lane’s Registration Statement on Form S-1 (File No. 333-215846), as amended.
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
About Hamilton Lane
Hamilton Lane (NASDAQ:HLNE) is a leading alternative investment management firm providing innovative private markets solutions to sophisticated investors around the world. Dedicated to private markets investing for 25 years, the firm currently employs more than 290 professionals operating in offices throughout the U.S., Europe, Asia, Latin America and the Middle East. With more than $332 billion in total assets under management and supervision as of December 31, 2016, Hamilton Lane offers a full range of investment products and services that enable clients to participate in the private markets asset class on a global and customized basis. For more information, please visit www.hamiltonlane.com, or follow Hamilton Lane on Twitter: @hamilton_lane.
CONTACT: Investor Contact Demetrius Sidberry [email protected] +1 610 617 6768 Media Contact Kate McGann [email protected] +1 610 617 5841